Scholarlink

Purpose <p>To evaluate the efficacy and safety of camrelizumab combined with apatinib in the treatment of <b>recurrent/metastatic</b> nasopharyngeal carcinoma (RM-NPC) and provide a basis for clinical application.</p> Methods <p>PubMed, Cochrane Library, Embase, and Web of Science databases were searched until July 19, 2024 for relevant studies. Data extraction and risk of bias assessment were conducted. Meta-analysis was performed using R software.</p> Results <p>Four single-arm trials with a total of 205 patients were included, with an overall survival rate of 78%, a progression-free survival rate of 45%, an objective response rate of 60%, and a disease control rate of 76%. Common adverse reactions were anemia (45%), leukopenia (46%), and fatigue (53%). The incidence of grade 3 or above adverse reactions was less than 10%, except for hypertension (16%).</p> Conclusion <p>Camrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis

  • 期刊论文

  • 发表日期：

    2025年5月31日

查看全文
  • Yanmei Li,
  • Yongfu Liang,
  • Peichang Ye,
  • Guoan Chen,
  • Yimin Zhang,
  • Meixia Chen,
  • Wenhua Xiong,
  • Xiuhao Yang,
  • Xiaowen Zhang

摘要

Purpose

To evaluate the efficacy and safety of camrelizumab combined with apatinib in the treatment of recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) and provide a basis for clinical application.

Methods

PubMed, Cochrane Library, Embase, and Web of Science databases were searched until July 19, 2024 for relevant studies. Data extraction and risk of bias assessment were conducted. Meta-analysis was performed using R software.

Results

Four single-arm trials with a total of 205 patients were included, with an overall survival rate of 78%, a progression-free survival rate of 45%, an objective response rate of 60%, and a disease control rate of 76%. Common adverse reactions were anemia (45%), leukopenia (46%), and fatigue (53%). The incidence of grade 3 or above adverse reactions was less than 10%, except for hypertension (16%).

Conclusion

Camrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies.